ES2103468T3 - Tratamiento de la inflamacion intestinal. - Google Patents

Tratamiento de la inflamacion intestinal.

Info

Publication number
ES2103468T3
ES2103468T3 ES93904830T ES93904830T ES2103468T3 ES 2103468 T3 ES2103468 T3 ES 2103468T3 ES 93904830 T ES93904830 T ES 93904830T ES 93904830 T ES93904830 T ES 93904830T ES 2103468 T3 ES2103468 T3 ES 2103468T3
Authority
ES
Spain
Prior art keywords
treatment
intestinal inflammation
tissus
ibd
endothelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93904830T
Other languages
English (en)
Inventor
Roy R Lobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25268692&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2103468(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ES2103468T3 publication Critical patent/ES2103468T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

SE DESCRIBE UN METODO PARA EL TRATAMIENTO DE (IBD) (INFLAMMATORY BOWEL DISEASE O). EL METODO COMPRENDE LA ADMINISTRACION DE UN ANTICUERPO, POLIPEPTIDO U OTRA MOLECULA COMPRENDIENDO VLA-4, UNA MOLECULA SUPERFICIAL EXPRESADA EN LA MAYOR CLASE DE TIPOS DE GLOBULOS SANGUINEOS BLANCOS E IMPLICADA EN LA ADHERENCIA DE LEUCOCITOS AL ENDOTELIO Y OTROS TEJIDOS EN EL TUBO DIGESTIVO.
ES93904830T 1992-02-12 1993-02-02 Tratamiento de la inflamacion intestinal. Expired - Lifetime ES2103468T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83513992A 1992-02-12 1992-02-12

Publications (1)

Publication Number Publication Date
ES2103468T3 true ES2103468T3 (es) 1997-09-16

Family

ID=25268692

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93904830T Expired - Lifetime ES2103468T3 (es) 1992-02-12 1993-02-02 Tratamiento de la inflamacion intestinal.

Country Status (11)

Country Link
EP (1) EP0625912B1 (es)
JP (3) JPH07506566A (es)
AT (1) ATE151642T1 (es)
AU (1) AU674302B2 (es)
CA (1) CA2129637C (es)
DE (1) DE69309906T2 (es)
DK (1) DK0625912T3 (es)
ES (1) ES2103468T3 (es)
GR (1) GR3024041T3 (es)
HK (1) HK1007683A1 (es)
WO (1) WO1993015764A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DE69309487T2 (de) 1992-11-13 1997-10-23 Univ Washington Peripheralisierung hämatopoietischer stammzellen
JP3593343B2 (ja) * 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
EP1759709B1 (en) * 1994-01-25 2013-02-27 Elan Pharmaceuticals Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
SI1113810T1 (sl) 1998-09-14 2009-04-30 Univ Texas Postopki za zdravljenje multiplega mieloma in kostne resorpcije, inducirane z mielomom, z uporabo antagonistov integrin/receptorske vezave
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
ATE464299T1 (de) 2002-02-20 2010-04-15 Ajinomoto Kk Neues phenylalaninderivat
ATE512163T1 (de) 2002-02-25 2011-06-15 Elan Pharm Inc Verabreichung von mitteln zur behandlung von entzündungen
NZ548420A (en) 2003-12-22 2010-03-26 Ajinomoto Kk Novel phenylalanine derivative
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP4652356B2 (ja) 2007-02-26 2011-03-16 アルプス電気株式会社 ターンシグナルスイッチ装置
ES2525065T3 (es) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
ES2805873T3 (es) 2010-04-16 2021-02-15 Biogen Ma Inc Anticuerpos anti-VLA-4
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX354101B (es) 2011-05-02 2018-02-13 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI -A4ß7.
CN109884295B (zh) * 2017-12-25 2022-03-08 苏州和锐生物科技有限公司 假单胞菌多肽、抗体捕获器件及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3852374T2 (de) * 1987-11-02 1995-05-04 Baylor College Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DK162890D0 (da) 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
EP0610298A1 (en) * 1991-10-01 1994-08-17 The General Hospital Corporation Preventing allograft rejection with antibodies to adhesion molecules

Also Published As

Publication number Publication date
JP4108572B2 (ja) 2008-06-25
WO1993015764A1 (en) 1993-08-19
DK0625912T3 (da) 1997-10-27
AU674302B2 (en) 1996-12-19
CA2129637A1 (en) 1993-08-19
EP0625912A1 (en) 1994-11-30
JPH07506566A (ja) 1995-07-20
JP2007045843A (ja) 2007-02-22
EP0625912B1 (en) 1997-04-16
AU3605993A (en) 1993-09-03
JP2004002472A (ja) 2004-01-08
GR3024041T3 (en) 1997-10-31
DE69309906D1 (de) 1997-05-22
DE69309906T2 (de) 1997-11-06
HK1007683A1 (en) 1999-04-23
ATE151642T1 (de) 1997-05-15
CA2129637C (en) 1999-05-04

Similar Documents

Publication Publication Date Title
ES2103468T3 (es) Tratamiento de la inflamacion intestinal.
DE69636327D1 (de) System zum sammeln von blut ohne es zu beschädigen
Evans et al. Localisation of collagen types and fibronectin in cartilage by immunofluorescence.
ATE150319T1 (de) Behandlung von asthma
FR2633940B3 (fr) Scleroglucane traite au glyoxal et son procede d'obtention
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
DE68927459T2 (de) Nachweis einer neurologischen Krankheit oder einer Funktionsstörung
DK31088A (da) Blodkoaguleringsnedsaettende peptidderivater
CA2034881A1 (en) Factor x-laci hybrid protein
FR2714327B1 (fr) Procédé et appareil de fixation d'un joint sur le bord périphérique d'un article.
EP0937982A3 (de) Diagnostikum und Therapeutikum zur Behandlung der autoimmunen Hepatitis
DE69025294D1 (de) Pump- und Behandlungssystem für Blut
ES2043900T3 (es) Conjugados de haptenos y proteinas y su utilizacion.
SE8904007D0 (sv) Monoklona antikroppar och diagnostiseringsmetod
ES2049021T3 (es) Metodo de recuperar la proteina epi purificada a partir de una solucion, especialmente una solucion de fermentacion.
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
RU96109171A (ru) Способ идентификации тела погибшего
DE69529405T2 (de) Pd-ecgf / thymidin phosphorylase spezifischer monoklonaler antikörper
FR2737209B1 (fr) Peptide capable d'etre reconnu par des anticorps reconnaissant l'antigene c33 du virus de l'hepatite c
RU93004826A (ru) Способ мездрения кож и шкур
DE69023500D1 (de) Verfahren zum nachweis von antikörpern gegen streptokinase.
UA15941A (uk) Спосіб діагhостики початкових стадій гіпертоhічhої хвороби
RU95105698A (ru) Способ получения сыворотки против pasteurella multocida
SE9302457D0 (sv) A novel anticoagulant entity, antibodies reacting specifically with the enety, and diagnostic and therapeutic uses of the entity
DE69123724T2 (de) Verfahren zur diagnose von hiv-infektionen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625912

Country of ref document: ES